Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | acetylcholinesterase | 0.0745 | 1 | 1 |
Mycobacterium tuberculosis | Probable flavin-containing monoamine oxidase AofH (amine oxidase) (MAO) | 0.0544 | 0.5382 | 0.5 |
Schistosoma mansoni | glutamate receptor NMDA | 0.0673 | 0.8334 | 0.5231 |
Mycobacterium ulcerans | flavin-containing monoamine oxidase AofH | 0.0586 | 0.6333 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.0745 | 1 | 1 |
Echinococcus granulosus | nmda type glutamate receptor | 0.0399 | 0.2024 | 0.2024 |
Echinococcus granulosus | carboxylesterase 5A | 0.0745 | 1 | 1 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0745 | 1 | 0.5 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0745 | 1 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.0745 | 1 | 1 |
Echinococcus multilocularis | carboxylesterase 5A | 0.0745 | 1 | 1 |
Brugia malayi | Carboxylesterase family protein | 0.0745 | 1 | 0.5 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0356 | 0.1037 | 0.1037 |
Loa Loa (eye worm) | hypothetical protein | 0.0745 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0745 | 1 | 0.5 |
Echinococcus granulosus | glutamate NMDA receptor subunit | 0.0673 | 0.8334 | 0.8334 |
Echinococcus multilocularis | acetylcholinesterase | 0.0745 | 1 | 1 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0399 | 0.2024 | 0.2024 |
Mycobacterium ulcerans | flavin-containing monoamine oxidase AofH | 0.0586 | 0.6333 | 0.5 |
Echinococcus multilocularis | glutamate (NMDA) receptor subunit | 0.0673 | 0.8334 | 0.8334 |
Loa Loa (eye worm) | carboxylesterase | 0.0745 | 1 | 0.5 |
Echinococcus granulosus | nmda type glutamate receptor | 0.0356 | 0.1037 | 0.1037 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Log IC50 (binding) | = 3.12 | Inhibitory activity against N9 neuraminidase subtype | ChEMBL. | 11300878 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.